Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 20

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 20
---
 different than the information you receive from other public companies in which you hold stock.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period for adopting new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Corporate Information

The Company was formed as a limited liability company in the state of Maryland in December 2012 and was converted to a C corporation in August 2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma Acquisition Corp. Inc. (“Acquisition Corp.”), pursuant to which Shuttle Pharmaceuticals, Inc. became a subsidiary of Acquisition Corp. and we subsequently changed the name of Acquisition Corp. to Shuttle Pharmaceuticals Holdings, Inc.

Our executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879 and our telephone number is (240) 430-4212. Our corporate website is www.shuttlepharma.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports, if any, are available to you free of charge through the “Investor Relations” section of our website as soon as reasonably practicable after such materials have been electronically filed with or furnished to the SEC. Information contained on our websites does not form a part of this prospectus.

| 11 |

<div align='center'>THE OFFERING</div>

| Common                                             
 stock offered by selling stockholders:             | 1,793,739                                                                                                                             
 shares of common stock1                                                                                                               |
| Common                                             
 stock outstanding before this offering:            | 4,076,568                                                                                                                             
 shares of common stock2                                                                                                               |
| Common                                             
 stock outstanding immediately after this offering: | 5,870,307                                                                                                                             
 shares (assuming full exercise of the Warrants).                                                                                      |
| Dividend                                           
 policy:                                            | We                                                                                                                                    
 have never paid cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future.      
 See the section entitled “Dividend Policy.”                                                                                           |
| Use                                                
 of proceeds: